Characterization of olanzapine (LY170053) in human liver slices by liquid chromatography/tandem mass spectrometry

  • J Mass Spectrom. 1998 Dec;33(12):1237-45. doi: 10.1002/(SICI)1096-9888(199812)33:12<1237::AID-JMS742>3.0.CO;2-F.
A T Murphy  1 ,  B G Lake ,  J R Bernstein ,  R B Franklin ,  T A Gillespie
Affiliations
  • 1. Department of Drug Metabolism and Disposition, Lilly Research Laboratories, Indianapolis, IN 46285, USA. [email protected]
PMID: 9875525 DOI: 10.1002/(SICI)1096-9888(199812)33:12<1237::AID-JMS742>3.0.CO;2-F
Abstract

Olanzapine metabolism was investigated using incubation of olanzapine with human liver slices. The intent of the investigation was to identify olanzapine metabolites and determine if the human liver slice incubations could potentially produce quantities of the olanzapine glucuronides for future studies. Along with known Phase 1 olanzapine metabolites, N-desmethyl-, 2-hydroxymethyl-, and 4'-N-oxide-, a new hydroxylated species was detected. Detection of Phase 2 metabolites included known N-10-glucuronides, a quaternary glucuronide and a novel glucuronide conjugate. This investigation showed the feasibility of using human liver slices to produce sufficient quantities of olanzapine glucuronides for further studies.

Products